Diseases

Researchers May Have Found A Biomarker For Alzheimer’s Disease

Discovering whether or not somebody is going to develop Alzheimer’s could revolutionize the treatment of a terrible disease which affects millions of individuals every year. Currently there might be hope on the horizon because researchers claim they’ve discovered a non-invasive accurate test for the condition.

Among the troubles with attempting to develop a way to cure Alzheimer’s is that the fact that by the time someone has been diagnosed with the disease, it’s often too late. There are no proven methods to reverse Alzheimer’once it’s set in s, meaning that there’s been a great deal of focus on attempting to find a way in which researchers and doctors could detect the disease before the symptoms set in.

Again this increases issues. To be able to confirm that a marker for Alzheimer’s disease has been identified, researchers must monitor the patients in their studies. It’s too late to do anything to Stop its progression, if they manage to spot any markers.      

But this hasn’t prevented many groups of researchers from searching for the elusive biomarkers, with many diverse paths having been explored. 1 avenue is looking in the cerebrospinal fluid of individuals for proteinss called beta-amyloids, as it’s been indicated that these can change with the progression of the disease. But others are keen to find approaches.

This latest study, published in Human Brain Mapping, used magnetoencephalography to scan the brains of individuals reporting the symptoms of Alzheimer’s in addition to those of individuals who were not,  recording their brain activity. They discovered that in men and women, the areas of the brain reacted to auditory tests, while in individuals with Alzheimer’s symptoms, they didn’t.

“It is highly probable that these individuals were seized in a preclinical [Alzheimer’s] stage because they reveal both neuropsychological and neurophysiological impairments characteristic of an [Alzheimer’s] form of dementia, though they didn’t yet meet clinical standards for the early stage of symptomatic [Alzheimer’s],” said Sanja Josef Golubic, the study’s lead author.  

The scientists claim that their evaluation is extremely accurate in picking up on the early signs of the disease, and it might be significant, if it proves effective in tests. It’s vital, nevertheless, to note that the sample size with this initial research was very small, with just 20 people so evidence will be required before it could be used.

Read more: http://www.iflscience.com

Most Popular

To Top